CD4 and myelodysplastic syndrome: The study of Fozza et al. showed that among patients with MDS or AML with myelodysplastic changes, responders to 5′-AZA (only six patients with MDS included) showed a progressive restoration in CDR3 diversity with a decrease in the skewing of TCR repertoire profiles in peripheral blood samples after treatment, especially in the CD4+ T cell subpopulation but with a similar trend in CD8+ T cells, as well [34].